Single Agent Regorafenib in Refractory Advanced Biliary Cancers
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02115542|
Recruitment Status : Completed
First Posted : April 16, 2014
Results First Posted : January 13, 2020
Last Update Posted : October 12, 2021
- Study Details
- Tabular View
- Study Results
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Cancer of the Bile Duct||Drug: Regorafenib||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||39 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Multi Institutional Phase II Trial of Single Agent Regorafenib in Refractory Advanced Biliary Cancers|
|Actual Study Start Date :||June 5, 2014|
|Actual Primary Completion Date :||December 10, 2018|
|Actual Study Completion Date :||September 20, 2021|
Experimental: Regorafenib Monotherapy
Regorafenib is administered as monotherapy during the study. 160 mg once daily (QD) will be administered for 3 weeks on /1 week off. One cycle is 28 days.
Four 40 mg regorafenib tables should be taken in the morning with approximately 8 fluid ounces (240 mL) of water after a low-fat (<30% fat) breakfast.
- Overall Survival (OS) at 6 Months [ Time Frame: at 6 month follow-up ]OS will be defined as the time from starting on trial to date of death due to any cause. The final analysis will be conducted after the follow-time of the last patient exceeds 6 months.
- Disease Control Response (DCR) [ Time Frame: Post 6 months follow-up, up to 13 months from on treatment per participant ]DCR defined as Complete Response (CR) + Partial Response (PR)+ Stable Disease (SD). CR: Complete disappearance of all target and non-target lesions (with the exception of lymph nodes mentioned below); No new lesions. PR: Applies only to patients with at least one measurable lesion; Greater than or equal to 30% decrease under baseline of the sum of appropriate diameters of all target measurable lesions; No unequivocal progression of nonmeasurable disease; No new lesions. SD: Does not qualify for CR, PR, Progression or Symptomatic Deterioration.
- Progression Free Survival (PFS) [ Time Frame: Post 6 months follow-up, up to 13 months from on treatment per participant ]
PFS is defined as the duration of time from start of treatment to time of progression or death, whichever comes first.
Progression - One or more of the following must occur: 20% increase in the sum of appropriate diameters of target measurable lesions over smallest sum observed (over baseline if no decrease during therapy) using the same techniques as baseline, as well as an absolute increase of at least 0.5 cm. Unequivocal progression of non-measurable disease in the opinion of the treating physician (an explanation must be provided). Appearance of any new lesion/site.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Histologically or cytologically documented carcinoma primary to the intra- or extra-hepatic biliary system or gall bladder with clinical and/or radiologic evidence of unresectable, locally advanced or metastatic disease. Patients with ampullary carcinoma are not eligible.
- Have failed no more than 2 prior lines of systemic chemotherapy for advanced biliary cancer. Patients who received adjuvant chemotherapy and had evidence of disease recurrence within 6 months of completion of the adjuvant treatment are also eligible. If patient received adjuvant treatment and had disease recurrence after 6 months, they will only be eligible after failing one line of systemic chemotherapy used to treat the disease recurrence.
- Eastern Cooperative Oncology Group (ECOG) Performance Status Assessment of 0 or 1
- Measurable and non-measurable disease will be allowed.
- Must not have been treated with any vascular endothelial growth factor (VEGF) inhibitors. Prior 5-Fluorouracil (5-FU) or capecitabine treatment is allowed only if given as a radiosensitizer concurrently with radiation therapy at least 12 weeks prior to registration or if given as part of any adjuvant therapy regimen > 6 months prior to study enrollment.
- Life expectancy of at least 12 weeks (3 months)
- For patients who have received prior cryotherapy, radiofrequency ablation, therasphere, ethanol injection, transarterial chemoembolization (TACE) or photodynamic therapy, the following criteria must be met: 28 days have elapsed since that therapy (lesions that have not been treated with local therapy must be present and measureable.
- Able to understand and willing to sign the written informed consent form
- All acute toxic effects of any prior treatment have resolved to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v4.0 Grade 1 or less at the time of signing the Informed Consent Form (ICF).
- Adequate bone marrow and liver function
- Participants can receive 5-FU or capecitabine.
- Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of study drug.
- Men and women of childbearing potential must agree to use adequate contraception beginning at the signing of the ICF until at least 3 months after the last dose of study drug.
- Able to swallow and retain oral medication
- Previous assignment to treatment during this study. Participants permanently withdrawn from study participation will not be allowed to re-enter study.
- Other investigational treatment during or within 21 days before starting study treatment
- Child Pugh B and C
- Uncontrolled hypertension (systolic pressure >140 mm Hg or diastolic pressure > 90 mm Hg [NCI-CTCAE v4.0] on repeated measurement) despite optimal medical management
- Active or clinically significant cardiac disease
- Evidence or history of bleeding diathesis or coagulopathy
- Any hemorrhage or bleeding event ≥ NCI CTCAE Grade 3 within 4 weeks prior to start of study medication
- Participants with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism within 6 months of informed consent
- Active malignancy except for nonmelanoma skin cancer or in situ cervical cancer. Potential participants surviving a cancer that was curatively treated and without evidence of disease for more than 3 years before the trial are allowed. All cancer treatments must be completed at least 3 years prior to study entry (i.e., signature date of the informed consent form).
- Potential participants with phaeochromocytoma
- Potential participants with severe hepatic impairment (Child-Pugh Class C)
- Known history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapy.
- Ongoing infection > Grade 2 NCI-CTCAE v4.0
- Symptomatic metastatic brain or meningeal tumors
- Presence of a non-healing wound, non-healing ulcer, or bone fracture
- Renal failure requiring hemo-or peritoneal dialysis
- Patients with seizure disorder requiring medication
- Persistent proteinuria >/= Grade 3 NCI-CTCAE v4.0 (> 3.5 g/24 hours, measured by urine protein:creatinine ratio on a random urine sample)
- Interstitial lung disease with ongoing signs and symptoms at the time of informed consent
- Pleural effusion or ascites that causes respiratory compromise (≥ NCI-CTCAE version 4.0 Grade 2 dyspnea)
- History of organ allograft (including corneal transplant)
- Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial
- Any malabsorption condition
- Women who are pregnant or breast-feeding
- Any condition which, in the investigator's opinion, makes the potential participant unsuitable for trial participation
- Substance abuse, medical, psychological or social conditions that may interfere with participation in the study or evaluation of the study results
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02115542
|United States, Florida|
|H. Lee Moffitt Cancer Center and Research Institute|
|Tampa, Florida, United States, 33612|
|United States, North Carolina|
|UNC Lineberger Comprehensive Cancer Center|
|Chapel Hill, North Carolina, United States, 27514|
|United States, Virginia|
|VCU Massey Cancer Center|
|Richmond, Virginia, United States, 23298|
|Principal Investigator:||Richard Kim, M.D.||H. Lee Moffitt Cancer Center and Research Institute|
Documents provided by H. Lee Moffitt Cancer Center and Research Institute:
|Responsible Party:||H. Lee Moffitt Cancer Center and Research Institute|
|Other Study ID Numbers:||
|First Posted:||April 16, 2014 Key Record Dates|
|Results First Posted:||January 13, 2020|
|Last Update Posted:||October 12, 2021|
|Last Verified:||September 2021|
Refractory Advanced Biliary Cancers
intra-hepatic biliary system
extra-hepatic biliary system
Bile Duct Diseases
Bile Duct Neoplasms
Biliary Tract Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Biliary Tract Diseases
Digestive System Diseases
Bile Duct Diseases